Track 12: CAR T-cell therapy

In CAR T-cell therapy, T cells are extracted from the patient's blood and altered in the laboratory by adding a gene for a receptor (known as a chimeric antigen receptor, or CAR), which aids the T cells in adhering to a particular cancer cell antigen. The patient is subsequently given their CAR T cells back.

Each CAR is created for a particular cancer's antigen since many malignancies have various antigens. For instance, the cancer cells in some types of leukaemia or lymphoma express the antigen CD19. The CAR T-cell treatments used to treat these tumours are designed to bind to the CD19 antigen and will not be effective against tumours lacking this antigen.


    Related Conference of Track 12: CAR T-cell therapy

    April 16-17, 2026

    19th World Congress on Stem Cell Research

    Tokyo, Japan
    June 08-09, 2026

    9th Global Conference on Cell and Gene Therapy

    Rome, Italy
    June 15-16, 2026

    22nd Global Summit on Stem Cell & Regenerative Medicine

    Amsterdam, Netherlands
    June 15-16, 2026

    13th World Congress on Epigenetics and Chromosome

    Paris, France
    June 18-19, 2026

    19th International Conference on Genomics & Pharmacogenomics

    Singapore City, Singapore
    September 25-26, 2025

    6th Annual summit on Cell Signaling and Cancer Therapy

    Montreal, Canada

    Track 12: CAR T-cell therapy Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in